Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)

被引：11

作者：

Facchinetti, Francesco ^{[1
]}

Pilotto, Sara ^{[2
]}

Metro, Giulio ^{[3
]}

Baldini, Editta ^{[4
]}

Bertolaccini, Luca ^{[5
]}

Cappuzzo, Federico ^{[6
]}

Delmonte, Angelo ^{[7
]}

Gasparini, Stefano ^{[8
,9
]}

Inno, Alessandro ^{[10
]}

Marchetti, Antonio ^{[11
]}

Passiglia, Francesco ^{[12
]}

Puma, Francesco ^{[13
]}

Ricardi, Umberto ^{[14
]}

Rossi, Antonio ^{[15
]}

Crino, Lucio ^{[7
]}

Novellol, Silvia ^{[12
]}

机构：

[1] Univ Paris Saclay, INSERM, U981, Gustave Roussy Canc Campus, Villejuif, France

[2] Univ Verona, Verona Univ Hosp, Med Oncol, Verona, Italy

[3] Azienda Osped Perugia, Santa Maria Misericordia Hosp, Med Oncol, Perugia, Italy

[4] S Luca Hosp, Dept Oncol, Lucca, Italy

[5] IRCCS, European Inst Oncol, IEO, Div Thorac Surg, Milan, Italy

[6] AUSL Romagna, Dept Oncol & Hematol, Ravenna, Italy

[7] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy

[8] Polytech Univ Marche Reg, Dept Biol Sci & Publ Hlth, Ancona, Italy

[9] Azienda Osped Riuniti, Pulm Dis Unit, Ancona, Italy

[10] IRCCS Osped Sacro Cuore Don Calabria, Med Oncol, Verona, Italy

[11] Ctr Excellence Aging Univ Fdn, Ctr Predict Mol Med, Chieti, Italy

[12] Univ Turin, San Luigi Hosp, Dept Oncol, Orbassano, Italy

[13] Univ Perugia, S Maria Misericordia Hosp, Div Thorac Surg, Med Sch, Perugia, Italy

[14] Univ Torino, Dept Oncol, Radiat Oncol, Turin, Italy

[15] Fdn IRCCS Casa Sollievo Sofferenza, Div Med Oncol, Foggia, Italy

来源：

TUMORI JOURNAL | 2019年 / 105卷

关键词：

AIOM; non-small cell lung cancer; guidelines; recommendations; RANDOMIZED PHASE-III; PACLITAXEL PLUS CARBOPLATIN; PLATINUM-BASED CHEMOTHERAPY; TYROSINE KINASE INHIBITORS; FACTOR RECEPTOR MUTATIONS; UNCOMMON EGFR MUTATIONS; WILD-TYPE EGFR; OPEN-LABEL; 1ST-LINE TREATMENT; ELDERLY-PATIENTS;

D O I：

10.1177/0300891619857418

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment landscape of metastatic non-small cell lung cancer (NSCLC) has dramatically evolved in recent years, since the recognition of several clinical-biological entities requiring personalized treatment approaches, leading to significant improvements in patients' survival outcomes. In particular, targeted therapies acting against EGFR, ALK, and ROS1, and immunotherapeutic agents modulating the PD-1/PD-L1 axis, represent new milestones in the treatment of advanced disease, supporting a chemotherapy backbone within a multidisciplinary model. The Italian Association of Medical Oncology (AIOM) has developed evidence-based guidelines for the management of lung tumors. Given the epidemiologic relevance, this report is dedicated to the treatment of advanced/metastatic NSCLC. These guidelines serve as a practical tool for oncologists, physicians, and other healthcare professionals to easily embrace the updated key points of NSCLC treatment strategies. Considering the upcoming introduction of potential new standards of care in several disease settings, these guidelines represent a benchmark from which to move forward.

引用

页码：3 / 14

页数：12

共 105 条

[1]

ALBERTI W, 1995, BRIT MED J, V311, P899

[2]

[Anonymous], ANN ONCOL

[3]

[Anonymous], ANN ONCOL S8

[4]

[Anonymous], NUM CANCR IT 2018

[5]

[Anonymous], 2018, Ann Oncol

[6] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[7]

BORGHAEI H, 2018, J CLIN ONCOL S, V36

[8] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[9] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer [J].

Camidge, D. R. ;

Kim, H. R. ;

Ahn, M. -J. ;

Yang, J. C. -H. ;

Han, J. -Y. ;

Lee, J. -S. ;

Hochmair, M. J. ;

Li, J. Y. -C. ;

Chang, G. -C. ;

Lee, K. H. ;

Gridelli, C. ;

Delmonte, A. ;

Garcia Campelo, R. ;

Kim, D. -W. ;

Bearz, A. ;

Griesinger, F. ;

Morabito, A. ;

Felip, E. ;

Califano, R. ;

Ghosh, S. ;

Spira, A. ;

Gettinger, S. N. ;

Tiseo, M. ;

Gupta, N. ;

Haney, J. ;

Kerstein, D. ;

Popat, S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2027-2039

[10] A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer [J].

Camidge, D. Ross ;

Gadgeel, Shirish M. ;

Weems, Garry Alan ;

Wilkins, H. Jeffrey ;

Johnson, Melissa Lynne .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 6 7 8 9 10 →